Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.73 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2044710 | 1.00 | SIGMAR1 (0.73) | SIGMAR1HRH3SLC6A4SLC6A3MEN1 | |
| SCHEMBL30819491 | 0.84 | SLC6A3 (0.73) | SIGMAR1HRH3SLC6A4SLC6A3LTA4H | |
| SCHEMBL10669091 | 0.82 | HRH3 (1.00) | SIGMAR1HRH3SLC6A4LTA4H | |
| SCHEMBL5271881 | 0.82 | AOC3 (0.66) | SIGMAR1MEN1KMT2A | |
| SCHEMBL17294993 | 0.81 | HRH3 (0.97) | SIGMAR1HRH3SLC6A4LTA4H | |
| SCHEMBL22813625 | 0.80 | HRH3 (0.83) | SIGMAR1HRH3SLC6A4SLC6A3LTA4H | |
| Hydrochloric Acid SCHEMBL10352286 | 0.78 | HRH3 (0.78) | SIGMAR1HRH3SLC6A4SLC6A3KMT2A | |
| SCHEMBL467014 | 0.75 | SIGMAR1 (1.00) | SIGMAR1SLC6A4SLC6A3 | |
| SCHEMBL11655881 | 0.75 | AOC3 (0.64) | SIGMAR1 | |
| SCHEMBL5708997 | 0.74 | HRH3 (0.72) | SIGMAR1HRH3KMT2ALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132484-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132484-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | EIF2AK2, MAVS, IRF3 | SIGMAR1 3739/4885HRH3 4492/4885SLC6A4 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.